Several Akt-inhibitors, such as MK2206, capivasertib (AZD5363), afuresertib (GSK2110183) and ipatasertib have been developed to target AKT signalling in vitro and in vivo; however, none of them has yet received FDA approval for cancer treatment. The gene discussed is AKT1; the disease is cancer.